FDA-regulated workflow components enable clinical laboratories to design their own assays for use on the NextSeq 550Dx instrument*.
The TruSight Tumor 170 workflow covers 170 genes associated with common solid tumors. It simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types.
Investigate the protein-coding regions of the genome to uncover genetic influences on disease and population health.
Comprehensively target disease-associated regions of the exome with high analytical sensitivity and specificity.
* Contact your Illumina representative for more information about IVD development partnerships
The NextSeq 550Dx instrument is intended for targeted sequencing of DNA libraries from human genomic DNA extracted from peripheral whole blood or formalin-fixed, paraffin-embedded (FFPE) tissue, when used for in vitro diagnostic (IVD) assays performed on the instrument. The NextSeq 550Dx instrument is not intended for whole genome or de novo sequencing. The NextSeq 550Dx instrument is to be used with registered and listed, cleared or approved, IVD reagents and analytical software.
The NextSeq 550Dx instrument is intended for sequencing of DNA libraries when used with in vitro diagnostic (IVD) assays performed on the instrument. The NextSeq 550Dx instrument is to be used with specific registered, certified or approved IVD reagents and analytical software.